Cadrenal Therapeutics, Inc.
CVKD Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$0.96
1.0%What Cadrenal Therapeutics, Inc. does
No business description yet.
- Legal name
- Cadrenal Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001213900-26-036946
0001937993
Revenue and margins
Cadrenal Therapeutics, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$12.6M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Cadrenal Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 63.5%.
Balance sheet
Cash, debt and the ratios that show how comfortably Cadrenal Therapeutics, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $8.4M | $10.0M | $4.0M |
| Interest coverage | −2,180.8x | — | — |
| Current ratio | 10.3x | 3.8x | 2.7x |
| Quick ratio | 10.3x | 3.8x | 2.7x |
| Total assets | $8.5M | $10.1M | $4.3M |
| Total liabilities | $0.8M | $2.7M | $1.6M |
| Shareholders' equity | $7.7M | $7.4M | $2.7M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✕ | ✕ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −56.7% | −35.3% | −8.8% |
| Altman Z'' | 3.88 | −7.83 | −44.31 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $4.1M | $4.2M | $4.1M |
| Operating income | −$7.6M | −$11.0M | −$13.5M |
| Interest expense | $0.0M | — | — |
| Pretax income | −$8.4M | −$10.7M | −$13.2M |
| Net income | −$8.4M | −$10.7M | −$13.2M |
| Net income to common | −$8.4M | −$10.7M | −$13.2M |
| Diluted EPS | −$9.29 | −$8.73 | −$6.64 |
| Diluted shares | 0.00B | 0.00B | 0.00B |
| Cash flow | |||
| Cash from operations | −$3.5M | −$7.4M | −$12.6M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$3.5M | −$7.4M | −$12.6M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $0.7M | $1.4M | $1.9M |
| Balance sheet | |||
| Cash and short-term investments | $8.4M | $10.0M | $4.0M |
| Current assets | $8.5M | $10.1M | $4.3M |
| Current liabilities | $0.8M | $2.7M | $1.6M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M |
| Total assets | $8.5M | $10.1M | $4.3M |
| Total liabilities | $0.8M | $2.7M | $1.6M |
| Shareholders' equity | $7.7M | $7.4M | $2.7M |
| Returns | |||
| Return on capital employed | −99.2% | −147.3% | −491.5% |
| Return on equity | −108.6% | −140.8% | −260.1% |
| Return on assets | −98.1% | −114.3% | −183.2% |
| Return on tangible equity | −108.6% | −143.2% | −483.3% |
| Growth | |||
| Share count change | — | 35.6% | 63.5% |
| Financial health | |||
| Interest coverage | −2,180.8x | — | — |
| Current ratio | 10.3x | 3.8x | 2.7x |
| Quick ratio | 10.3x | 3.8x | 2.7x |
| Quality scores | |||
| Altman Z'' | 3.9 | −7.8 | −44.3 |
| Accruals ratio | −56.7% | −35.3% | −8.8% |
Source: SEC EDGAR XBRL filings (CIK 0001937993). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.